• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

不同肝纤维化生物标志物对严重肥胖和非酒精性脂肪性肝病患者肝科转诊的影响。

Impact of using different biomarkers of liver fibrosis on hepatologic referral of individuals with severe obesity and NAFLD.

机构信息

Department of Medicine and Rehabilitation, Policlinico Di Monza, Via Modigliani 10, 20900, Monza, MB, Italy.

Department of Medicine and Surgery, Università degli Studi di Milano Bicocca, Milan, Italy.

出版信息

J Endocrinol Invest. 2020 Jul;43(7):1019-1026. doi: 10.1007/s40618-020-01188-7. Epub 2020 Feb 1.

DOI:10.1007/s40618-020-01188-7
PMID:32008185
Abstract

PURPOSE

The purpose of this study was to estimate how many individuals with severe obesity and NAFLD should be referred to hepatologists according to the EASL-EASD-EASO guidelines and whether the choice of specific indicators of liver fibrosis would significantly impact the number of referrals.

METHODS

This was a single-center retrospective study of 495 individuals with severe obesity screened at our institution between 2012 and 2018 for a bariatric surgery intervention. The guidelines were applied using the NAFLD Liver Fat Score (NLFS) to assess the presence of steatosis and the NAFLD fibrosis score (NFS), Fibrosis-4 (FIB-4) and Hepamet Fibrosis Score (HFS) to assess the risk of advanced fibrosis.

RESULTS

Three hundred and seventy-nine patients (76.6%) had evidence of liver steatosis. The application of the guidelines would lead to referral of 66.3% of patients using NFS, 31.7% using FIB-4 and 34.2% using HFS. When referrals due to abnormal liver function tests were excluded, these percentages dropped to 55.8%, 7.3% and 12.1%, respectively. The strongest inter-biomarker agreement was found between FIB-4 and HFS (κ = 0.86, 95% CI 0.815-0.910).

CONCLUSION

Strict application of the guidelines in individuals with severe obesity would probably lead to over-referral, although a great variability exists among the different scores.

摘要

目的

本研究旨在根据 EASL-EASD-EASO 指南估计应将多少名严重肥胖和非酒精性脂肪性肝病(NAFLD)患者转介给肝病专家,以及选择特定的肝纤维化指标是否会显著影响转介人数。

方法

这是一项单中心回顾性研究,纳入了 2012 年至 2018 年在我院接受减重手术干预的 495 名严重肥胖患者。使用非酒精性脂肪性肝病肝脂肪评分(NLFS)评估脂肪变性的存在,使用 NAFLD 纤维化评分(NFS)、纤维化-4 指数(FIB-4)和 Hepamet 纤维化评分(HFS)评估进展性纤维化的风险。

结果

379 例(76.6%)患者有肝脂肪变性的证据。应用指南将导致 66.3%的患者使用 NFS、31.7%的患者使用 FIB-4 和 34.2%的患者使用 HFS 转介。排除肝功能异常的转介后,这些百分比分别降至 55.8%、7.3%和 12.1%。FIB-4 和 HFS 之间的一致性最强(κ=0.86,95%CI 0.815-0.910)。

结论

在严重肥胖患者中严格应用指南可能会导致过度转介,尽管不同评分之间存在很大差异。

相似文献

1
Impact of using different biomarkers of liver fibrosis on hepatologic referral of individuals with severe obesity and NAFLD.不同肝纤维化生物标志物对严重肥胖和非酒精性脂肪性肝病患者肝科转诊的影响。
J Endocrinol Invest. 2020 Jul;43(7):1019-1026. doi: 10.1007/s40618-020-01188-7. Epub 2020 Feb 1.
2
EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral?EASL-EASD-EASO 临床实践指南:严重肥胖人群非酒精性脂肪性肝病的管理——是否导致过度转诊?
Diabetologia. 2017 Jul;60(7):1218-1222. doi: 10.1007/s00125-017-4264-9. Epub 2017 Mar 28.
3
Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications.使用非侵入性评分对2型糖尿病患者进行非酒精性脂肪性肝病筛查及其与糖尿病并发症的关联
BMJ Open Diabetes Res Care. 2020 Feb;8(1). doi: 10.1136/bmjdrc-2019-000904.
4
Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.Hepamet纤维化评分系统的开发与验证——一种用于识别非酒精性脂肪性肝病伴晚期纤维化患者的简单无创检测方法
Clin Gastroenterol Hepatol. 2020 Jan;18(1):216-225.e5. doi: 10.1016/j.cgh.2019.05.051. Epub 2019 Jun 11.
5
Screening strategies for nonalcoholic fatty liver disease in type 2 diabetes: Insights from NHANES 2005-2016.2 型糖尿病中非酒精性脂肪肝疾病的筛查策略:来自 NHANES 2005-2016 的见解。
Diabetes Res Clin Pract. 2020 Sep;167:108358. doi: 10.1016/j.diabres.2020.108358. Epub 2020 Jul 31.
6
Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population.三种非侵入性纤维化评分(Hepamet、FIB-4、NAFLD 纤维化评分)在混合拉丁美洲人群中 NAFLD 患者中的诊断性能。
Ann Hepatol. 2020 Nov-Dec;19(6):622-626. doi: 10.1016/j.aohep.2020.08.066. Epub 2020 Sep 9.
7
Weight Loss After Bariatric Surgery Predicts an Improvement in the Non-alcoholic Fatty Liver Disease (NAFLD) Fibrosis Score.减重手术后体重减轻可预测非酒精性脂肪性肝病(NAFLD)纤维化评分的改善。
Obes Surg. 2019 Apr;29(4):1295-1300. doi: 10.1007/s11695-018-03676-5.
8
Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease.应用 ELF 试验、FIB-4 和 NAFLD 纤维化评分对人群进行肝病筛查。
J Hepatol. 2023 Aug;79(2):277-286. doi: 10.1016/j.jhep.2023.04.002. Epub 2023 Apr 21.
9
Bariatric Surgery as an Efficient Treatment for Non-Alcoholic Fatty Liver Disease in a Prospective Study with 1-Year Follow-up : BariScan Study.前瞻性研究随访 1 年:BariScan 研究显示减重手术可有效治疗非酒精性脂肪性肝病。
Obes Surg. 2018 May;28(5):1342-1350. doi: 10.1007/s11695-017-3012-z.
10
Modified thresholds for fibrosis risk scores in nonalcoholic fatty liver disease are necessary in the obese.在肥胖人群中,非酒精性脂肪性肝病的纤维化风险评分需要修改阈值。
Obes Surg. 2017 Jan;27(1):115-125. doi: 10.1007/s11695-016-2246-5.

引用本文的文献

1
Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment.2型糖尿病患者的非酒精性脂肪性肝病:筛查、诊断与治疗
J Clin Med. 2023 Aug 27;12(17):5597. doi: 10.3390/jcm12175597.
2
Comparison of Pathway Referrals for Liver Fibrosis Risk Stratification Performed in Diabetology and Nutrition Clinics.糖尿病学和营养诊所中用于肝纤维化风险分层的通路转诊比较。
Diabetes Metab Syndr Obes. 2023 Jun 8;16:1721-1729. doi: 10.2147/DMSO.S407511. eCollection 2023.
3
Application of Scores Assessing Histological Activity and Estimated Long-Term Risk Analysis of Hepatic Decompensation of Non-Alcoholic Fatty Liver Disease in Individuals Undergoing Bariatric Surgery.
应用评分评估非酒精性脂肪性肝病患者行减重手术后的肝组织学活动和估计长期肝失代偿风险。
Obes Surg. 2023 May;33(5):1580-1586. doi: 10.1007/s11695-023-06568-5. Epub 2023 Apr 1.
4
NAFLD: Mechanisms, Treatments, and Biomarkers.非酒精性脂肪性肝病:发病机制、治疗方法及生物标志物
Biomolecules. 2022 Jun 13;12(6):824. doi: 10.3390/biom12060824.
5
Patients with type 2 diabetes and elevated fibrosis-4 are under-referred to hepatology and have unrecognized hepatic decompensation.2 型糖尿病伴纤维化 4 升高的患者转至肝病科的比例较低,存在未被识别的肝失代偿。
J Gastroenterol Hepatol. 2022 Sep;37(9):1815-1821. doi: 10.1111/jgh.15900. Epub 2022 Jun 15.
6
Potential biomarkers in the fibrosis progression of nonalcoholic steatohepatitis (NASH).非酒精性脂肪性肝炎(NASH)纤维化进展中的潜在生物标志物。
J Endocrinol Invest. 2022 Jul;45(7):1379-1392. doi: 10.1007/s40618-022-01773-y. Epub 2022 Feb 28.
7
Prevalence of Elevated Liver Stiffness Among Potential Candidates for Bariatric Surgery in the United States.美国肥胖症手术潜在候选人中肝硬度升高的流行率。
Obes Surg. 2022 Mar;32(3):712-719. doi: 10.1007/s11695-021-05885-x. Epub 2022 Jan 5.